An alternative CRISPR-Cas nuclease for biotech & pharma
Specialty Chemicals has published an article on Akribion’s nuclease technology. Our colleagues Michael Krohn and Dirk Sombroek introduce its mode of action, and its benefits and advantages for different applications. If you are interested, you can read the article here.
The entire issue of Specialty Chemicals is available here.